Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
Thereafter, long-term safety considerations might favor transitioning to other medication classes based on individual response patterns and risk profiles
[9] [10] Semaglutide is FDA-approved for specific indications, and prescribing decisions should align with these approved uses rather than treating insulin resistance as an isolated condition
That is second order thinking
In some cases, adjusting your dose of semaglutide, combining it with other weight loss medications, or exploring alternative treatment options may be necessary to help you achieve your goals
Patients with type 2 diabetes already face altered bone metabolism compared to the general population